Study of Lenalidomide and Dexamethasone with or without Pembrolizumab in Newly Diagnosed and Treatment-Naïve Multiple Myeloma Compare the Progression Free Survival (PFS) as assessed by independent central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process Main objective : (1a) To demonstrate that at 1 month after the third dose of vaccine, both the modified process vaccine and COMVAX™ will induce adequate seroprotection rates (SPR, % of subjects with...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

MERCK SERONO 28062 : Essai de phase 1 visant à déterminer la dose maximale tolérée de 2 schémas d'administration d'un inhibiteur de MEK (AS703026), chez des patients ayant une tumeur solide. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A multicenter, open label, phase I trial of the MEK inhibitor AS703026 given orally to subjects with solid tumours

• Pays France
• Organes Tumeurs solides
• Spécialités Thérapies Ciblées

A Phase IV multicentre, randomised, double-blind, placebo controlled, trial to evaluate the safety and efficacy of Raptiva ® in the treatment of subjects with moderate to severe plaque psoriasis involving hands and/or feet, with or without pustules To evaluate the safety and efficacy of Raptiva ® against placebo to control chronic moderate to severe plaque-type psoriasis involving hands and/or feet scoring PGA (PGA - H&F) ≥3 in subjects not suit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer -Evaluate PFS per RECIST 1.1 by blinded independent radiologists’ review of all subjects with recurrent/progressive metastatic urothelial cancer treated with pembrolizumab (MK-3475) compared to paclit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options This program is designed to provide expanded access to MK-0518 prior to the product’s approval and availability on the market. The safety and tolerability of MK-0518 400 mg b.i.d. for the treatment o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase IIa Open Label, Randomized Clinical Trial to Study Vintafolide and Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using SPECT/CT scan with Etarfolatide (EC20) for Subject Selection Ensayo clínico de fase IIa abierto y aleatorizado para estudiar Vintafolide y paclitaxel en pacientes con cáncer de mama triplemente negativo avanzado, con selección de pacientes mediante etarfolatide (EC20) To evaluate the progression-free survival of vintafolide monotherapy relative to paclitaxel and the progression-free survival of vintafolide + paclitaxel combination therapy relative to paclitaxel in...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of CANCIDAS in Children types of ungal infections The main objectives of this study are to evaluate the safety, tolerability, and efficacy of caspofungin therapy, administered as 50 mg/m2 IV once daily (maximum 70 mg/day) following a loading dose of ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Therapy After 6 weeks of treatment, to assess the effect of the addition of MK 0941 compared with the addition of glimepiride on 24-hour weighted mean glucose (24-hour WMG).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Merck START : Essai de phase 3 randomisé visant à déterminer si le vaccin anticancéreux Stimuvax® est efficace pour prolonger la vie, chez des patients ayant un cancer du poumon non à petites cellules de stade III non résécable. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est de déterminer si le vaccin anticancéreux Stimuvax® est efficace pour prolonger la durée de vie des patients ayant un cancer du poumon non à petites cellules non opérable. ...

• Pays France
• Organes Poumon, type non à petites cellules
• Spécialités Immunothérapie - Vaccinothérapie, Chimiothérapie